Fannyhessea vaginae (F. vaginae)

Atopobium vaginae (recently reclassified as Fannyhessea vaginae) is a Gram-positive, anaerobic, rod-shaped bacterium that serves as a highly specific and sensitive marker for bacterial vaginosis (BV) [1][2]. In the vaginal ecosystem, it often replaces healthy Lactobacillus species and participates in the formation of dense, polymicrobial biofilms, typically in association with Gardnerella vaginalis [3]. This biofilm structure is a critical factor in the pathogenesis of BV, as it provides a physical barrier against host immune responses and limits the penetration of antibiotics [3]. Clinically, the presence of A. vaginae is significant because it is frequently associated with the failure of standard metronidazole therapy due to its high level of intrinsic or acquired resistance to the drug [4]. Beyond localized vaginal infection, A. vaginae has been linked to more severe reproductive health issues, including pelvic inflammatory disease, late miscarriage, and preterm birth [5]. Consequently, it is a primary focus for the development of more effective antimicrobial strategies and diagnostic assays in women's health [2][4]. Sources: [1] Nouioui I, et al. (2018). Genome-Based Taxonomic Classification of the Phylum Actinobacteria. Front Microbiol. [2] Menard JP, et al. (2008). Molecular quantification of Gardnerella vaginalis and Atopobium vaginae loads to predict bacterial vaginosis. Clin Infect Dis. [3] Swidsinski A, et al. (2005). Adherent biofilms in bacterial vaginosis. Obstet Gynecol. [4] De Backer E, et al. (2006). Antibiotic susceptibility of Atopobium vaginae. BMC Infect Dis. [5] Haahr T, et al. (2016). Abnormal vaginal microbiota may be associated with poor reproductive outcomes. Hum Reprod.

Other names

Atopobium vaginaeAtopobium vaginae (reclassified)A. vaginae

Antibacterial agents target the organism through various mechanisms: Clindamycin inhibits protein synthesis by binding to the 50S ribosomal subunit; Nitroimidazoles (Metronidazole, Tinidazole) cause DNA strand breakage via reductive activation; Nifuratel interferes with several bacterial enzyme systems.